Study of Combined Oral Contraceptive Effects in Female Subjects

• Status: Completed
• Trial end date: 2014-08-25
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the effect of BMS-955176 on the pharmacokinetics of coadministered oral contraceptives.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb; ViiV Healthcare
• Collaborator: GlaxoSmithKline
• Treatments: BMS-955176; Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

1. Signed Written Informed Consent a) The signed informed consent form

2. Target population

• a) Healthy female subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results

• b) Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive, at screening and Day -1. BMI = weight (kg)/[height (m)]2

• c) Weight greater than or equal to 45 kg

• d) Subject Reenrollment: This study permits the reenrollment of a subject that has discontinued study as a pretreatment failure (ie, has not been treated). If reenrolled, the subject must be reconsented

3. Age and Reproductive Status

• a) Women, 18 to 40 years of age, inclusive

• b) Women of childbearing potential (WOCBP) with intact ovarian function as determined by medical history and history of regular menstrual cycles, and who have been on a stable regimen of Ortho Cyclen for at least 2 consecutive months without evidence of breakthrough bleeding or spotting, or subjects who have been using a stable regimen of another combination oral contraceptive containing EE for at least two months prior to dosing on Day 1 of Cycle 1 and willing to switch to Ortho Cyclen for the total duration of the study (approximately 78 days)

• c) Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to dosing on Day 1 of Cycle 1

• d) Women must not be breastfeeding

Exclusion Criteria:

Medical History and Concurrent Diseases

• a) Any significant acute or chronic medical illness

• b) History of biliary disorders, including Gilbert's disease or Dubin-Johnson disease

• c) Current or recent (within 3 months of dosing on Day 1 of Cycle 1) gastrointestinal disease

• d) Any major surgery within 4 weeks of dosing on Day 1 of Cycle 1

• e) Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug

• f) Donation of > 400 mL to a blood bank or in a clinical study (except a screening visit) within 8 weeks of dosing on Day 1 of Cycle 1

• g) Blood transfusion within 4 weeks of dosing on Day 1 of Cycle 1

• h) Inability to tolerate oral medication

• i) Inability to be venipunctured and/or tolerate venous access

• j) Smokers (those who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1 of Cycle 1)

• k) Recent (within 6 months of dosing on Day 1 of Cycle 1) drug or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV), Diagnostic Criteria for Drug and Alcohol Abuse

• l) Any other sound medical, psychiatric, and/or social reason as determined by the investigator